Graves病甲状腺及甲状腺外表现的管理:最新进展
本文为关于系统性自身免疫性Graves病(GD)及Graves眼病(GO)管理的特邀更新,基于指南、原始研究、系统综述和Meta分析。TSH受体抗体(TSH-R-Abs)是GD的特异性生物标志物,有助于甲亢的鉴别诊断和GD的准确快速诊断。全球范围内,硫酰胺类药物(首选甲巯咪唑)是新诊断GD的首选治疗(12-18个月),而持续高滴度TSH-R-Abs或18个月时仍甲亢或复发者可选择放射性碘或甲状腺全切,长期低剂量甲巯咪唑是安全替代。
要点
- TSH-R-Abs是GD特异性标志物,助力甲亢鉴别和快速诊断。
- 甲巯咪唑为初治GD首选,疗程12-18个月,失败者可选择根治治疗。
- 活动性GO患者避免放射性碘,尤其是吸烟者;妊娠早期首选丙硫氧嘧啶。
核心结论
- GD管理呈现血清学诊断和药物治疗的明确趋势。
研究设计与样本
- 特邀更新,证据来源于指南、相关原始文章、系统综述和Meta分析。
主要发现
- TSH-R-Abs是GD特异性生物标志物,有助于甲亢鉴别诊断和GD的准确快速诊断。
- 全球范围内硫酰胺类药物是新诊断GD的首选治疗,疗程12-18个月,甲巯咪唑为首选药物。
- 持续高滴度TSH-R-Abs和/或18个月时持续甲亢或甲巯咪唑疗程后复发者可选放射性碘或甲状腺全切。
- 长期低剂量甲巯咪唑是 valuable and safe 的替代方案。
- 活动性GO患者应避免放射性碘,尤其是吸烟者;妊娠早期首选丙硫氧嘧啶。
关键数值与推荐
- 硫酰胺类药物疗程12-18个月。
- 18个月时持续高TSH-R-Abs和/或持续甲亢,或甲巯咪唑疗程后复发,可考虑根治治疗。
- 妊娠早期首选丙硫氧嘧啶而非甲巯咪唑。
- 活动性GO患者避免放射性碘,尤其是吸烟者。
- 甲状腺全切应由高容量甲状腺外科医生实施。
临床怎么用
- 应用TSH-R-Abs辅助GD诊断和鉴别甲亢病因。
- 初治GD选择甲巯咪唑12-18个月,根据TSH-R-Abs和甲状腺功能决定后续治疗。
- 活动性GO患者避免放射性碘,吸烟者尤其注意;妊娠早期使用丙硫氧嘧啶。
- 甲状腺全切应由高容量外科医生执行。
- 非严重GO在COVID-19期间推迟全身激素治疗,提供局部治疗和预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO). EVIDENCE ACQUISITION: Guidelines, pertinent original articles, systemic reviews, and meta-analyses. EVIDENCE SYNTHESIS: Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistently high TSH-R-Abs and/or persistent hyperthyroidism at 18 months, or with a relapse after completing a course of MMI, can opt for a definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX). Continued long-term, low-dose MMI administration is a valuable and safe alternative. Patient choice, both at initial presentation of GD and at recurrence, should be emphasized. Propylthiouracil is preferred to MMI during the first trimester of pregnancy. TX is best performed by a high-volume thyroid surgeon. RAI should be avoided in GD patients with active GO, especially in smokers. Recently, a promising therapy with an anti-insulin-like growth factor-1 monoclonal antibody for patients with active/severe GO was approved by the Food and Drug Administration. COVID-19 infection is a risk factor for poorly controlled hyperthyroidism, which contributes to the infection-related mortality risk. If GO is not severe, systemic steroid treatment should be postponed during COVID-19 while local treatment and preventive measures are offered. CONCLUSIONS: A clear trend towards serological diagnosis and medical treatment of GD has emerged.
引用
- Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab. 2020. PMID: 32929476. doi:10.1210/clinem/dgaa646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。